NORMOZIDE (hydrochlorothiazide; labetalol hydrochloride) by Merck & Co. is mechanism of action lisinopril inhibits angiotensin-converting enzyme (ace) in human subjects and animals. Approved for hypertension. First approved in 1987.
Drug data last refreshed 16h ago · AI intelligence enriched 3w ago
NORMOZIDE is a fixed-dose combination oral tablet containing hydrochlorothiazide (a thiazide diuretic) and labetalol hydrochloride (a combined alpha/beta-adrenergic blocker) approved by Merck & Co. in 1987 for hypertension management. The drug lowers blood pressure through dual mechanisms: labetalol reduces sympathetic tone via adrenergic blockade while hydrochlorothiazide promotes sodium and water excretion, with complementary effects on potassium balance. It is indicated as monotherapy or add-on treatment for patients with elevated blood pressure who require dual-agent therapy.
As a legacy product approaching loss of exclusivity, NORMOZIDE faces declining market share and reduced commercial investment, with smaller brand teams focused on maintenance and cost management.
Mechanism of Action Lisinopril inhibits angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the…
Worked on NORMOZIDE at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
NORMOZIDE offers limited career growth opportunities due to its LOE-approaching lifecycle and minimal market investment relative to competing agents. Roles on this product are primarily defensive and focused on maintaining market share in remaining therapeutic segments rather than driving new patient acquisition or innovation.